PGEN Stock Recent News

–  Company strengthens focus on building and optimizing commercial readiness and pre-launch activities for PRGN-2012 in recurrent respiratory papillomatosis  – GERMANTOWN, Md. , July 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the appointment of Phil Tennant as the Company's chief commercial officer.

–   Phase 1/2 pivotal study met the primary safety and efficacy endpoints – –   51% (18 out of 35) of patients achieved Complete Response, requiring no surgeries after treatment with PRGN-2012; complete responses have been durable beyond 12 months with median duration of follow up of 20 months as of data cutoff – –   86% of patients (30 out of 35) had a decrease in surgical interventions in the year after PRGN-2012 treatment compared to the year prior to treatment; RRP surgeries reduced from a median of 4 pre-treatment to 0 post-treatment – –   PRGN-2012 was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2 – –   PRGN-2012 treatment induced HPV 6/11-specific T cell responses in RRP patients with a significantly greater expansion of peripheral HPV-specific T cells in responders compared with non-responders – –   PRGN-2012 significantly (p < 0.0001) improved Derkay and quality of life scores in c

GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the Company will host a webcast on June 3, 2024 at 6:00 PM CT/7:00 PM ET following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis.

GERMANTOWN, Md., Dec. 18, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 42nd Annual J.P.

Last week, I revealed five “jackpot” stocks to buy for 2024.

In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through penny stocks.

Precigen, Inc. (PGEN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PGEN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Precigen, Inc. (NASDAQ:PGEN ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Jennifer Kim - Cantor Fitzgerald Arthur He - H.C. Wainwright Ben Burnett - Stifel Brian Cheng - JPMorgan Operator Good morning and welcome to the Precigen Second Quarter and First Half 2023 Financial Results and Business Update Call.

High-risk penny stocks have long tempted investors with the potential for significant returns. However, it is crucial to acknowledge the inherent risks associated with these speculative investments.